![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Daewoong Bio Inc. Hwaseong-si Kr, based in South Korea, is a pharmaceutical company.
One of their significant offerings is Ursodeoxycholic acid, Process IV, supported by a 'Valid' Certificate of Suitability (CEP) with the number R0-CEP 2022-479 - Rev 00
This Chemical Type CEP, issued on March 31, 2023, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1275 associated with this CEP further emphasizes